Your browser doesn't support javascript.
loading
A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice.
Cui, Guozhen; Xin, Qiqi; Tseng, Hisa Hui Ling; Hoi, Maggie PuiMan; Wang, Yan; Yang, Binrui; Choi, InLeng; Wang, Yuqiang; Yuan, Rong; Chen, Keji; Cong, Weihong; Lee, Simon MingYuen.
Afiliação
  • Cui G; Zhuhai key laboratory of basic and applied research in Chinese medicine, Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
  • Xin Q; Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Tseng HHL; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
  • Hoi MP; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
  • Wang Y; Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China; National Integrated Traditional and Western Medicine Center for Cardiovascular Disease, China-Japan Friendship Hospital, Beijing, China.
  • Yang B; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
  • Choi I; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China.
  • Wang Y; Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, China.
  • Yuan R; Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China; Clinical Medical College, Beijing University of Chinese Medicine, Beijing, China.
  • Chen K; Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Cong W; Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: congcao@188.com.
  • Lee SM; State Key Laboratory of Quality Research in Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Macao, China. Electronic address: simonlee@umac.mo.
Pharmacol Res ; 134: 109-117, 2018 08.
Article em En | MEDLINE | ID: mdl-29890255
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilpropionatos / Pirazinas / Cicatrização / Bloqueadores dos Canais de Cálcio / Neovascularização Fisiológica / Canais de Cálcio Tipo L / Miócitos Cardíacos / Indutores da Angiogênese / Infarto do Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Pharmacol Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fenilpropionatos / Pirazinas / Cicatrização / Bloqueadores dos Canais de Cálcio / Neovascularização Fisiológica / Canais de Cálcio Tipo L / Miócitos Cardíacos / Indutores da Angiogênese / Infarto do Miocárdio Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Pharmacol Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: China